Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-chemotherapy recombinant human thrombopoietin to reduce chemotherapy-induced thrombocytopenia in AML
ChiCTR2100041866Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Anhui Medical University
- Start
- Jan 2021
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of recombinant human thrombopoietin in acute myeloid leukemia (AML) (2 arms), sponsored by First Affiliated Hospital of Anhui Medical University. Primary endpoints: Lowest platelet count, Duration of platelet count below 50×10^9/L and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
recombinant human thrombopoietin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2100041866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100041866.